Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?

Gupta, R

Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)? [electronic resource] - The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease Dec 2001 - 1078-9 p. digital

Publication Type: Journal Article; Review

1027-3719


Antitubercular Agents--therapeutic use
Government Programs--trends
Humans
International Cooperation
Isoniazid--therapeutic use
National Health Programs--trends
Practice Guidelines as Topic
Rifampin--therapeutic use
Tuberculosis, Multidrug-Resistant--drug therapy
World Health Organization